Medical/Pharmaceuticals

GSK's Omjjara (momelotinib) approved in Singapore as the first treatment indicated for myelofibrosis patients with anaemia

* Approval is for use in myelofibrosis patients with moderate to severe anaemia who are JAK-naive or previously treated with ruxolitinib * Nearly all myelofibrosis patients globally are estimated to develop anaemia over the course of the disease, and over 30% will discontinue treatment due to ...

2025-03-24 10:00 2218

ArkBio Announces the Completion of Phase III Clinical Study for AK0901 in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in China

SHANGHAI, March 24, 2025 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced the successful completion of the Phase III clinical study of AK0901, a novel drug for the treatment of attention deficit hyperactivity disorder (ADHD). This milestone represents a substant...

2025-03-24 09:00 3295

CStone Submits Application to the European Medicines Agency for New Indication of Sugemalimab in Stage III Non-Small Cell Lung Cancer

SUZHOU, China, March 23, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a biopharmaceutical company dedicated to developing innovative cancer therapies, today announced the submission of a Type II variation application to the European Medicines Agency (EMA) for sugemalimab. T...

2025-03-24 08:15 2963

Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for Platinum-resistant Ovarian Cancer

SAN FRANCISCO and SUZHOU, China, March 24, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmun...

2025-03-24 08:00 2876

AIM Vaccine's mRNA Shingles Vaccine Approved by the US FDA to Begin Clinical Trials, AI-Enabled mRNA Major Vaccine Product Development Accelerates

HONG KONG, March 24, 2025 /PRNewswire/ -- AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, published an announcement onMarch 23, 2025, the company's independently developed mRNA shingles vaccine has recently received clinical trial approval from the U.S. Food and Drug Administrati...

2025-03-24 08:00 2875

Clover Announces U.S. IND Clearance and Initiation of Revaccination Clinical Study for RSV Vaccine Candidate SCB-1019

-- U.S. IND clearance and revaccination trial initiation supports the differentiated global opportunity for Clover's RSV PreF vaccine (SCB-1019) utilizing validated Trimer-Tag platform -- -- Evaluation of SCB-1019 as part of a respiratory combination Trimer-Tagged PreF vaccine (RSV + hMPV ± PIV3...

2025-03-24 07:56 2359

Everest Medicines Announces FDA Clearance of IND Application for Tumor-Associated Antigen Vaccine EVM14

* EVM14 received U.S. FDA clearance for its IND application, becoming Everest's first internally discovered program, and the first mRNA therapeutic cancer vaccine to be cleared for global clinical development. * Preclinical highlights: * EVM14 induced a dose-dependent, antigen-specific immun...

2025-03-24 07:30 2748

Volpara Health Announces BOADICEA Integration and Record ECR 2025 Research Presence

CANBERRA, Australia, March 24, 2025 /PRNewswire/ -- Volpara Health, a global leader in AI-powered breast health solutions and a subsidiary of Lunit, today announced two major milestones: * Volpara density is now a validated input to the BOADICEA breast cancer risk model. * A record of 21 ind...

2025-03-24 05:00 1928

Aphranel® MagiCCrystal CaHA Filler from Shanghai MOYOM Biotec, Obtains NMPA Class III Medical Device Certificate in China

——The World's First Precisely Regulated Injectable CaHA Filler, Accelerating Compliance in the Medical Aesthetics Industry inChina. SHANGHAI, March 21, 2025 /PRNewswire/ -- Shanghai Moyom Biotechnology's high-profile brand,Aphranel® MagiCCrystal CaHA Filler, has officially obtained Class III Med...

2025-03-21 21:00 5452

Syneron Bio Announces Strategic Collaboration with AstraZeneca

BEIJING, March 21, 2025 /PRNewswire/ -- Syneron Bio, a cutting-edge oral macrocyclic peptide drug biotech company, announced today a strategic collaboration with the global biopharmaceutical leader AstraZeneca to develop potential first-in-class macrocyclic peptides for the treatment of chronic ...

2025-03-21 20:02 2560

Antengene Announces 2024 Full-Year Financial Results, Proprietary Programs Advancing to Pivotal Trials with Accelerating Multi-market Revenue Ramp Up

SHANGHAI and HONG KONG, March 21, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) today announced its full-year results for the period endingDecember 31, 2024, along with several significant milestones achieved in recent months. Dr. Jay Mei, Antengene's Founder,...

2025-03-21 19:29 4761

Harbour BioMed Enters into Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Generation Therapeutic Antibodies

SHANGHAI, CAMBRIDGE, Mass. and ROTTERDAM, Netherlands, March 21, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics in immunology and oncology, today announced a global ...

2025-03-21 19:21 2631

Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results

Strategic Acquisition of Intellectual Property of BRII-179, a Wholly Owned Phase 2b Asset Capable of Combining with Multiple HBV Treatment Modalities for Cure Data from Multiple Ongoing Late-Stage Studies Reinforce Brii Bio's HBV Functional Cure Strategy of Optimized Combination Regimens to Target...

2025-03-21 19:10 6167

Akeso's Cadonilimab Combined with Concurrent Chemoradiotherapy Demonstrates Promising Efficacy in Locally Advanced Cervical Cancer: Data Published at the 2025 SGO Annual Meeting

HONG KONG, March 20, 2025 /PRNewswire/ -- Akeso Inc. (9926.HK) presented promising phase III safety run-in results from the COMPASSION-18/AK104-305 study, at the 2025 Annual Meeting of the Society of Gynecologic Oncology (SGO). The study evaluates the global first-in-class PD-1/CTLA-4 bispecific ...

2025-03-21 11:14 2360

FDA Approves New Prostate Cancer Imaging Agent Gozellix®

MELBOURNE, Australia and INDIANAPOLIS, March 21, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces thatthe United States (U.S.) Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Gozellix® (TLX007-CDx, ki...

2025-03-21 08:38 2562

WuXi Biologics Named to CDP Water Security "A List" for Second Consecutive Year

* Launching the Water Excellence Stewardship (WES) program to advance UN Sustainable Development Goal 6 (SDG6) * Contributing to the 2025 World Water Day campaign to ensure the availability of water and sanitation for all SHANGHAI, March 20, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2...

2025-03-21 08:30 2150

Wounds hard to heal? Troubled by dressing changes? Dimora, Amazon's 3-year top brand, shows you the way.

NEW YORK, March 20, 2025 /PRNewswire/ -- Dimora Medical , a continuous innovator in high-end medical care supplies, has secured the number one spot in Amazon's Wound Dressings category for the third year. With over 33 million wound dressings sold since its 2019 debut,...

2025-03-21 01:08 3019

Noul Showcases AI-Powered Cervical Cancer Cell Screening Technology at NVIDIA GTC 2025

* Company Joins NVIDIA Healthcare & Life Sciences (HCLS) Ecosystem to Advance Global Diagnostic Accessibility and Seeks Partnerships with Global Healthcare Opportunities YONGIN, South Korea, March 20, 2025 /PRNewswire/ -- Noul Co., Ltd.  a Korea-based medical AI company, announced that it presen...

2025-03-21 00:00 3541

Menarini Group Announces Collaboration with VisualDx to Aid in Identifying People Who May Have Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

* BPDCN is an aggressive hematologic malignancy with a historically poor prognosis * VisualDx is a clinical decision support system used by more than 2,300 hospitals, clinics, and medical schools around the world  * VisualDx's system seeks to enhance identification of people who may have BP...

2025-03-20 22:29 2720

Seegene Unveils HPV Genotyping Solution at EUROGIN 2025

-    Presented a roadmap to enhance screening reliability at the world's leading multidisciplinary HPV congress held inPortugal from March 16-19 -    Demonstrated how self-collected samples for HPV testing can bridge gaps in cervical cancer screening and advance HPV screening goals SEOUL, South K...

2025-03-20 21:00 2343
1 ... 130131132133134135136 ... 646